SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs India to disinvest entire stake in Eye Kare Kilitch

16 Jan 2013 Evaluate

Kilitch Drugs India has received an approval to disinvest company’s entire stake held in Eye Kare Kilitch, being a non-listed company. The board at its meeting held on 15, 2013 has approved for the same.

This step is taken as the Board of Directors do not envisage any increase in growth on the said investment without any additional infusion of funds, which the board do not find feasible.

Kilitch Drugs (India) is engaged in the manufacture of injectibles such as gentamycin sulphate, dexamethason sodium phosphate, B-complex and others. Nasdaq-listed Akorn Inc is a niche generic pharmaceutical company.

Kilitch Drugs(India) Share Price

134.90 -0.20 (-0.15%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×